Cointime

ContraFect

company

About

ContraFect is a biotechnology company researching the use of monoclonal antibodies to treat life-threatening infectious diseases.

  • 1 - 10

Highlights

Total Funding Amount
$11.52M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Grant
Last Funding Money Raised
$7.20M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2008
Number Of Employee
1 - 10
Operating Status
Active

ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. Its novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria.

The company was founded in 2008 and is headquartered in Yonkers, New York.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$11.52M
ContraFect has raised a total of $11.52M in funding over 2 rounds. Their latest funding was raised on Jun 6, 2019 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 6, 2019 Grant $7.20M 1 Congressionally Directed Medical Research Programs — Detail
Aug 23, 2010 Series Unknown $4.32M 1 Equity Source Partners — Detail

Investors

Number of Lead Investors
Number of Investors
2
2
ContraFect is funded by 2 investors. Congressionally Directed Medical Research Programs and Equity Source Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Congressionally Directed Medical Research Programs Yes Grant
Equity Source Partners Yes Series Unknown
Cointime
เนื้อหา
บริษัท